approach & pipeline
DEFINED TARGETS.
BOUNDLESS IMPACT.
Dianthus Therapeutics is harnessing the power of selectivity to advance next-generation complement therapies to treat severe autoimmune diseases.
OUR INNOVATION
Our lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections.
Addressing both the disease and treatment burdens that disrupt the lives of patients.
OUR FOCUS
DNTH103 is an investigational, long-acting monoclonal antibody engineered to potently and selectively inhibit the active form of C1s, a clinically validated target in the classical complement pathway.
As the classical pathway plays a significant role in disease pathology across a range of neuromuscular disorders, DNTH103 holds the potential to be a pipeline in a product – beginning with generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.
Engineered with YTE half-life extension technology, DNTH103 is intended to be the first subcutaneous complement therapy that can be self-administered as infrequently as once every two weeks for patients with severe, classical pathway-driven autoimmune disorders.
So patients can live healthier lives to their fullest potential.
BUILDING A NEUROMUSCULAR FRANCHISE WITH DNTH103
Positive top-line Phase 1 data for DNTH103 from 60 healthy volunteers across eight single and multiple-ascending dose cohorts validate DNTH103’s potent classical pathway inhibition with an approximate 60-day extended half-life and a potentially differentiated safety profile. Dianthus is building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis in 1Q’24, the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in 3Q’24, and planned initiation of a Phase 3 trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE’24.
PIPELINE
DNTH103 – subcutaneous active C1s antibody
Approximately 60,000 people in the United States live with gMG, a chronic autoimmune disorder that causes progressive muscle weakness. About 85% of people with gMG have AChR autoantibody-driven disease, a driven by classical complement pathway activation.
Approximately 5,000 to 10,000 people in the United States live with MMN, a disease in which the immune system attacks peripheral nerve axons and myelin sheaths and classical complement pathway activation can facilitate progressive nerve damage. Up to 80% of patients are not adequately managed by current standard of care and there are no approved targeted biologic therapies for MMN.
Approximately 15,000 people in the United States live with CIDP, a neuromuscular condition driven by classical pathway activation that follows a relapsing-remitting or a progressive clinical course with the potential to result in substantial disability, loss of motor and sensory function. There are no approved targeted biologic therapies for CIDP.
Ongoing Discovery
